Cdk1 inhibitor is primarily used in cancer research and drug development due to its ability to halt cell cycle progression at the G2/M phase. By selectively inhibiting Cdk1, it prevents uncontrolled cell division, a hallmark of cancer. This makes it a valuable tool in studying tumor growth and evaluating potential anti-cancer therapies. It is also used to synchronize cells in cell culture studies, enabling researchers to examine specific stages of the cell cycle. Additionally, Cdk1 inhibitors are explored for their potential in treating diseases involving abnormal cell proliferation, including certain viral infections and neurodegenerative disorders where cell cycle re-entry plays a role.